)
Fluicell (FLUI) investor relations material
Fluicell Q1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Achieved the strongest quarterly financial results in company history, with significant revenue and profit growth year-over-year and sequentially from Q4 2025.
Revenue growth driven by multiple streams, notably product sales and development contracts, especially with Ambusol.
Strategic focus on two main projects: diabetes collaboration with Mayo Clinic and cancer therapy partnership with Ambusol.
Board renewal proposed, adding industry expertise and increasing shareholder representation.
Financial highlights
Net revenue for Q1 2026 was 6,094 KSEK, up 2,538% year-over-year and 59% sequentially from Q4 2025.
EBITDA reached 3,378 KSEK (vs. -2,541 KSEK Q1 2025); EBIT was 3,291 KSEK (vs. -2,644 KSEK Q1 2025).
Net income before tax was 3,309 KSEK (vs. -2,675 KSEK Q1 2025); EPS was 2.41 SEK (vs. -1.95 SEK Q1 2025).
Operating cash flow was 248 KSEK (vs. -3,795 KSEK Q1 2025); total cash flow after investments was -984 KSEK (vs. -6,216 KSEK Q1 2025).
Operating margin improved to 54% (vs. -1,145% Q1 2025); equity ratio at 68%.
Outlook and guidance
Management expects continued strong performance in 2026, with full-year result and cash flow forecasted between -1 MSEK and 1 MSEK.
Revenue growth expected to remain robust, though quarterly fluctuations may occur due to project timing.
Focus remains on expanding business in technology and regenerative medicine, targeting new pharma collaborations.
- Record Q4 sales and positive cash flow signal a strong turnaround and strategic progress.FLUI
Q4 202520 Feb 2026 - Q3 net sales surged 138% year-over-year, with 2026 guidance indicating near break-even.FLUI
Q3 202528 Nov 2025 - Revenues surged and losses narrowed, but new financing is needed to sustain operations.FLUI
Q2 202529 Aug 2025 - Q3 revenue surged 93% and losses narrowed, but external funding remains essential.FLUI
Q3 202413 Jun 2025 - Revenue fell on strategic refocus, but cost savings and new capital support future growth.FLUI
Q2 202413 Jun 2025 - Operating loss narrows as Fluicell advances regenerative medicine and diabetes therapy.FLUI
Q1 20256 Jun 2025 - Strategic shift and capital raises drove improved results and growth in tissue-based therapies.FLUI
Q4 20245 Jun 2025
Next Fluicell earnings date
Next Fluicell earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Explore our global coverage
)
)